Disney's "Avengers: Endgame" is now the highest-grossing film of all time having earned $2.79 billion at the global box office.Entertainmentread more
Peter Neupert worked for Microsoft and Amazon-backed Drugstore.com, where he got to know Jeff Bezos. He now advises start-ups.Technologyread more
Regional stability, oil prices and potential for war will all depend on what Iran does with its nuclear program in the event of the deal's termination.World Politicsread more
Instagram began tests that hide "like" counts on posts. That means influencers who market products on Instagram will have to rely on different metrics to show success.Technologyread more
Facebook Vice President David Marcus is the face of the company's Libra digital currency, but the original driving force was a 26-year-old female corporate-development...Technologyread more
Moving lots of data to a public cloud over the internet can take months or years. CNBC got an inside look at how AWS transfers data to the cloud for its clients.Technologyread more
Amazon's new policy for account suspensions doesn't go far enough to protect sellers from potentially unfair and wrongful suspensions, merchants say.Technologyread more
There is no end in sight to the Boeing 737 Max grounding after two fatal crashes, prompting airlines to rethink their growth plans.Airlinesread more
After a year of flooding, Midwest farmers face a stifling heat wave that's spreading across the U.S.Weather & Natural Disastersread more
On Saturday, Disney's Marvel Studios announced its upcoming slate of superhero films during a panel at San Diego Comic-Con.Entertainmentread more
"It troubles me that the most important political office in the world is becoming the face of racism and exclusion," Kaeser said in a Twitter post.Politicsread more
Pharmaceutical giant Johnson & Johnson is set to test an experimental HIV vaccine in the U.S. and Europe sometime this year, the company confirmed with CNBC.
The experimental J&J vaccine is a mosaic-based preventative immunization that targets various strains of the HIV virus.
About 1.1 million people in the U.S. and 2 million people in Europe live with HIV, a virus that attacks the body's immune system and makes a person more likely to become sick. If HIV is not treated, it can turn into AIDS, the late stage of HIV in which the virus badly damages the immune system. People with AIDS on average live about three years after their diagnosis, according to HIV.gov.
The company is also conducting a phase 2 clinical trial for the vaccine in Africa, in which 2,600 women in five southern African countries will be immunized. Initial results from that trial are expected by 2021, J&J said.
The J&J trial comes amid President Donald Trump's pledge to end the HIV epidemic in the United States by 2030, a goal which public health advocates have cheered and have sought for years. Pharmaceutical giant Gilead Sciences, which dominates the $26 billion-a-year HIV drug market, reached an agreement with the Trump administration to donate medications that reduce the risk of HIV transmission for up to 200,000 people a year until 2025.
In late April, J&J and GlaxoSmithKline majority-owned ViiV Healthcare filed a new drug application with the FDA for its once-a-month injection treatment for HIV. In March, the two companies posted late-stage data that showed the shot was as effective as standard daily pills for controlling HIV.
Bloomberg first reported the company's plan to conduct a clinical trial in the U.S. and Europe.